Experimental combo targets Hard-to-Treat stomach cancer
NCT ID NCT04768686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a new drug, FLX475, combined with the immunotherapy pembrolizumab (Keytruda) in 20 people with advanced or metastatic stomach cancer. The goal was to see if the combination could shrink tumors in patients who had already tried other treatments. The study included two groups based on whether the cancer was linked to the Epstein-Barr virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FLX475 (tablet) and pembrolizumab (IV infusion)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced gastric cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase study with only 20 participants enrolled. The results may not apply to all patients, and the combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
-
Gangnam Severance Hospital
Seoul, South Korea
-
Hanllym University Medical Center
Anyang-si, Gyeonggi-do, South Korea
-
Korea University Guro Hospital
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital
Seoul, South Korea
-
The Catholic University of Korea St. Vincent Hospital
Suwon, Gyeonggi-do, South Korea